Development and validation of quantification method for fluconazole in human serum using ultra-high-performance liquid chromatography-tandem mass spectrometry

Mohd Salleh Rofiee

QR Code Link :
Type :	article
Subject :	Q Science
Main Author :	Mohd Salleh Rofiee
Additional Authors :	Muhammad Hisyam Jamari Teh, Lay Kek Mohd Zaki Salleh
Title :	Development and validation of quantification method for fluconazole in human serum using ultra-high-performance liquid chromatography-tandem mass spectrometry

Place of Production :	Tanjong Malim
Publisher :	Fakulti Sains dan Matematik
Year of Publication :	2022
Corporate Name :	Universiti Pendidikan Sultan Idris

Abstract : Universiti Pendidikan Sultan Idris

Fluconazole is one of the commonly prescribed antifungal with recommendation for therapeutic level monitoring to ensure its levels are within therapeutic range to reduce the risk of adverse effects, toxicity of this otherwise safe drug and to prevent occurence of resistant fungi. A sensitive and robust method was developed to quantitate the level of fluconazole in human serum using ultra-high performance liquid chromatography-tandem mass spectrometry. Using Agilent SB-C18 column (50 x 2.1mm, 1.8 μm particle size), fluconazole was eluted separately from the internal standard using mobile phase (A) 0.1% formic acid in water and (B) methanol. The flow rate was set at 0.4 mL/min in positive ionization mode. The method was linear from 156.25 ng/mL to 5,000 ng/mL (r2 = 0.999) with the recovery of 80-90%, and the accuracy and precision of 89-101% and 0-10%, respectively. Fluconazole was also proven stable under different test conditions with the accuracy of 87-114%. The developed method met the guidelines drawn by the European Medicines Agency, Food and Drug Administration and International Council of Harmonisation. The method used for purification of samples prior to injection was user-friendly and robust.

References

Adedoyin, A., Fancourt, C., Menzel, K., Zhao, T., Tomek, C., Panebianco, D. & Iwamoto, M. (2020). Assessment of pharmacokinetic interaction between letermovir and fluconazole in healthy participants. Clinical Pharmacology in Drug Development, 10(2), 198-206

Andes, D., Pascual, A., & Marchetti, O. (2008). Antifungal therapeutic drug monitoring: Established and emerging indications. Antimicrobial Agents and Chemotherapy, 53(1), 24-34.

Ashbee, H., Barnes, R., Johnson, E., Richardson, M., Gorton, R., & Hope, W. (2013). Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. Journal of Antimicrobial Chemotherapy, 69(5), 1162-1176.

Bapiro, T.E., Richards, F.M., & Jodrell, D.I. (2016). Understanding the complexity of porous graphitic carbon (PGC) chromatography: Modulation of mobile-stationary phase interactions overcomes loss of retention and reduces variability. Analytical Chemistry, 88(12), 6190-6194.

Clissold, S. P. (1990). Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs, 39, 877-916.

European Medicines Agency (2011). Guideline on bioanalytical method validation.

Franklin, I., Elias, E., & Hirsch, C. (1990). Fluconazole-induced jaundice. The Lancet, 336(8714), 565-565.

Hillis, J., Morelli, I., Neville, D., Fox, J., & Leary, A.C. (2004). The validation of a bioanalytical method for the determination of fluconazole in human plasma. Chromatographia, 59(2), S203-S207.

Hope, W., Billaud, E., Lestner, J., & Denning, D. (2008). Therapeutic drug monitoring for triazoles. Current Opinion in Infectious Diseases, 21(6), 580-586.

ICH Harmonised Tripartite Guideline (2005). Validation of Analytical Procedures: Text and Methodology.

Jessome, L.L., & Volmer, D.A. (2006). Ion suppression: a major concern in mass spectrometry. Lc Gc North America, 24(5), 498.

Kyle, J.A. (2010). The fungus among us: an antifungal review. US Pharm, 35(8), 44-56.

Liew, K.B., Loh, G. O. K., Tan, Y. T. F., & Peh, K. K. (2012). Development and application of simple HPLC UV method for fluconazole quantification in human plasma. International Journal of Pharmacy and Pharmaceutical Sciences, 4(4), 107-11

Lopez-Rangel, E., & Van Allen, M. (2005). Prenatal exposure to fluconazole: An identifiable dysmorphic phenotype. Birth Defects Research Part A: Clinical and Molecular Teratology, 73(11), 919-923.

Mau, S., Salamone, F.R., Muller, R.J., & Polsky, B.W. (1989). Trimetrexate, ganciclovir, foscarnet and fluconazole: investigational drugs used in the management of AIDS. Hospital Pharmacy, 24, 209-215.

McMahon, J., & Grayson, M. (2008). Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis. American Journal of Health-System Pharmacy, 65(7), 619-623

Müller, C., Gehlen, D., Blaich, C., Prozeller, D., Liss, B., Streichert, T., & Wiesen, M. H. (2017). Reliable and Easy-To-Use Liquid Chromatography–Tandem Mass Spectrometry Method for Simultaneous Analysis of Fluconazole, Isavuconazole, Itraconazole, Hydroxy-Itraconazole, Posaconazole, and Voriconazole in Human Plasma and Serum. Therapeutic Drug Monitoring, 39(5), 505-513.

Muńoz, P., Moreno, S., Berenguer, J., de Quiros, J. B., & Bouza, E. (1991). Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome. Archives of Internal Medicine, 151(5), 1020-1021.

Nair, D.R., & Morris, H.H. (1999). Potential fluconazole-induced carbamazepine toxicity. Annals of Pharmacotherapy, 33(7-8), 790-792.

Norgaard, M., Pedersen, L., Gislum, M., Erichsen, R., Sogaard, K., Schonheyder, H., & Sorensen, H. (2008). Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. Journal of Antimicrobial Chemotherapy, 62(1), 172-176.

Rençber, S., Karavana, S.Y., Yilmaz, F.F., Eraç, B., Nenni, M., Gurer-Orhan, H., Limoncu, M.H., Guneri, P. & Ertan, G. (2019). Formulation and evaluation of fluconazole loaded oral strips for local treatment of oral candidiasis. Journal of Drug Delivery Science and Technology, 49, 615-621.

Stern, J.J., Hartman, B.J., Sharkey, P., Rowland, V., Squires, K.E., Murray, H.W., & Graybill, J.R. (1988). Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. The American Journal of Medicine, 85(4), 477-480.

Sugar, A.M., & Saunders, C. (1988). Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. The American Journal of Medicine, 85(4), 481-489.

U.S Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine (2018). Bioanalytical Method Validation Guidance for Industry.

World Health Organization. (2015). WHO model list of essential medicines: 19th list, April 2015.

Xiao, Y., Xu, Y.K., Pattengale, P., O'Gorman, M.R., & Fu, X. (2017). A rapid high-performance LC-MS/MS method for therapeutic drug monitoring of voriconazole, posaconazole, fluconazole, and itraconazole in human serum. The Journal of Applied Laboratory Medicine, 1(6), 626-636

Yamreudeewong, W., Lopez-Anaya, A., & Rappaport, H. (1993). Stability of fluconazole in an extemporaneously prepared oral liquid. American Journal of Health-System Pharmacy, 50(11), 2366-2367.

This material may be protected under Copyright Act which governs the making of photocopies or reproductions of copyrighted materials.
You may use the digitized material for private study, scholarship, or research.

Back to previous page